Delphi Diagnostics Announces New Publication Confirming EAI Predicts Benefit from Weekly Paclitaxel in HR+/HER2− Breast Cancer
This analysis independently validated previous findings and further helps to establish EAI as the first genomic assay shown to predict benefit from a contemporary taxane-based chemotherapy regimen in HR+/HER2− breast cancer. For a PDF of this press release, click here HOUSTON, June 22,...
This analysis independently validated previous findings and further helps to establish EAI as the first genomic assay shown to predict benefit from a contemporary taxane-based chemotherapy regimen in HR+/HER2− breast cancer. For a PDF of this press release, click here HOUSTON, June 22,...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.